CYBERMED LIFE - ORGANIC  & NATURAL LIVING

Cybermedlife - Therapeutic Actions NK Cell Activity

Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell mediated lysis of cancer stem cells. 📎

Abstract Title: Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell mediated lysis of cancer stem cells. Abstract Source: Curr Drug Deliv. 2012 Jan ;9(1):5-16. PMID: 22023212 Abstract Author(s): Anahid Jewett, Han-Ching Tseng, Aida Arasteh, Saba Saadat, Russell E Christensen, Nicholas A Cacalano Article Affiliation: The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, Los Angeles, CA 90095-1668, USA. This email address is being protected from spambots. You need JavaScript enabled to view it. Abstract: Mounting effective anti-tumor immune responses by cytotoxic effectors is important for the clearance of tumors. However, accumulated evidence suggests that the cytotoxic function of immune effectors is largely suppressed in the tumor microenvironment by a number of distinct effectors and their secreted factors. The aims of this review are to provide a rationale and potential mechanism for immunosuppression in cancer, and to demonstrate the significance of such immunosuppression in cellular differentiation and tissue regeneration in pathological conditions, and progression of cancer. We have recently shown that increased NK cell function was seen when they were cultured with primary oral squamous carcinoma stem cells (OSCSCs) as compared to their more differentiated oral squamous carcinoma cells (OSCCs). In addition, human embryonic stem cells (hESCs), Mesenchymal Stem Cells (hMSCs), dental pulp stem cells (hDPSCs) and induced pluripotent stem cells (hiPSCs) were significantly more susceptible to NK cell mediated cytotoxicity than their differentiated counterparts or parental cells from which they were derived. We have also reported that inhibition of differentiation or reversion of cells to a less-differentiated phenotype by blocking NFκB or targeted knock down of COX2 augmented NK cell function significantly. Total population of monocytes and those depleted of CD16(+) subsets were able to substantially prevent NK cell mediated lysis of OSCSCs, MSCs and DPSCs. Taken together, our results suggest that stem cells are significant targets of the NK cell cytotoxicity. The concept of split anergy in NK cells and its contribution to tissue repair and regeneration and in tumor resistance and progression will be discussed in this review. Therefore, patients with cancer may benefit from repeated allogeneic NK cell transplantation atthe site of the tumor for specific elimination of cancer stem cells. Article Published Date : Dec 31, 2011
Therapeutic Actions NK Cell Activity

NCBI pubmed

IFNG-AS1 Enhances Interferon Gamma Production in Human Natural Killer Cells.

Related Articles IFNG-AS1 Enhances Interferon Gamma Production in Human Natural Killer Cells. iScience. 2019 Jan 03;11:466-473 Authors: Stein N, Berhani O, Schmiedel D, Duev-Cohen A, Seidel E, Kol I, Tsukerman P, Hecht M, Reches A, Gamliel M, Obeidat A, Charpak-Amikam Y, Yamin R, Mandelboim O Abstract Long, non-coding RNAs (lncRNAs) are involved in the regulation of many cellular processes. The lncRNA IFNG-AS1 was found to strongly influence the responses to several pathogens in mice by increasing interferon gamma (IFNγ) secretion. Studies have looked at IFNG-AS1 in T cells, yet IFNG-AS1 function in natural killer cells (NKs), an important source of IFNγ, remains unknown. Here, we show a previously undescribed sequence of IFNG-AS1 and report that it may be more abundant in cells than previously thought. Using primary human NKs and an NK line with IFNG-AS1 overexpression, we show that IFNG-AS1 is quickly induced upon NK cell activation, and that IFNG-AS1 overexpression leads to increased IFNγ secretion. Taken together, our work expands IFNG-AS1's activity to the innate arm of the type I immune response, helping to explain its notable effect in animal models of disease. PMID: 30661002 [PubMed - as supplied by publisher]
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok Decline